⬤ Loading…
McKesson
…
NYSE: MCK Healthcare Medical Distribution 🔎 Screen
S&P 500
🏹 Trader: 🚀 Stage 2 + Near High 📈 Stage 2 🎯 Near 52W High | BRS 85 Ready View all →
📈 Stage 2 detected Find the fundamental catalyst → → run Growth Triggers in Ask AI
$121.1B
Market Cap
22.3
P/E
1.34
PEG
35.9%
ROCE
N/M
ROE
-10.54
D/E
1.6%
OPM
0.0%
% from 52W High
83
α RS
🔍 MCK is showing a multi-screen setup because it matches 11 of 39 tracked screener presets, Sector RRG has Health Care in the Leading quadrant with the trail still strengthening, RS Rating is 83, and it has maintained a 24-day Near 52-Week High momentum persistence. The main caution: the Institutional Quality preset's Backtest win rate is only 44.1%. Net: Mixed signal stack, not a recommendation. ? Conviction RRG RS Rating Momentum Streaks Backtest
Sources
Conviction 11/39 · Health Care in Leading quadrant · RS Rating 83 · Near 52-Week High streak: 24d · Backtest win rate 44.1%
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for MCK including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
— Excellent
— Good
— Average
— Poor
By Category
📊 Peer Medians
About

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding MCK
View All Superinvestors →
Manager Shares Value % of Fund Period
Jim Simons Renaissance Technologies LLC 117.2K $101.5M 0.16% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Confident Specific → Stable 5 quarters Full tone analysis in Intelligence →
Good quarter Investor Presentation One-Pager? Q1 2027
Revenue
$105.4B
+8% YoY
Adjusted Operating Profit
$1.7B
+16% YoY
Operating Margin
1.6%
+0.1pp YoY
Net Income Attributable to McKesson
$614M
-22% YoY
What Went Right
  • Adjusted EPS jumped 20% to $9.93, beating expectations and driving a full-year EPS guidance raise.
  • Three segments grew operating profit double digits: North American Pharma +19%, Oncology & Multispecialty +41%, and RxTS +13%.
  • GLP-1 distribution revenue reached $15B, up 24% YoY; Oncology & Multispecialty revenues rose 33% to $14.2B.
  • Returned $2.6B to shareholders in Q1, including $2.25B of accelerated share repurchases.
What to Watch
  • Medical-Surgical operating profit fell 20% to $195M on product mix and one-time administrative expense.
  • Q2 will lap a $51M prior-year gain in Oncology & Multispecialty and $25M of Norway operating profit.
  • Q1 benefited from timing of new product launches and early generic favorability that may not repeat later in the year.
  • Policy risks remain: 340B reform, IRA Part B, and WAC pricing dynamics are still uncertain.
Management Guidance
  • Fiscal 2027 adjusted EPS guidance raised to $44.20-$45.00 from $43.80-$44.60, implying 13%-15% EPS growth.
  • Fiscal 2027 revenue growth expected at 5%-9% and operating profit growth at 9%-13%.
  • Segment guidance: NAP revenue +4%-8%, op profit at high end of 5.5%-9.5%; O&M revenue +14.5%-18.5%, op profit +13.5%-17.5%; RxTS revenue +2.5%-6.5%, op profit +11%-15%; Med-Surg revenue +1%-6%, op profit flat to +4%.
  • Free cash flow guided to ~$4.5-$4.9B; about $5B of share repurchases planned; diluted shares expected at 115.5M-117.5M.
  • No Q2 revenue guidance provided; full-year outlook updated.
Investor Lens
The investment thesis looks stronger after this call. Q1 showed broad-based momentum — NAP, Oncology, and RxTS all delivered double-digit operating profit growth — and management used that confidence to raise full-year EPS guidance. GLP-1, oncology, and biopharma services remain durable growth engines, while the Medical-Surgical separation is progressing with Apollo capital, a standalone credit facility and the new Wellverse brand. The main watch items are Q2 comparison headwinds, policy-driven dynamics around 340B and IRA, and whether Q1's launch/timing benefits can sustain. Overall, the balance of execution and forward guidance tilts positively.
From investor presentation · AI-generated analysis · Not investment advice
🔒
Premium Feature
Investor Presentation One-Pager — quarterly highlights, what went right/wrong & management guidance
Upgrade to Premium
Already a member? Log in
📈 STRONG Strong Q1: EPS +20%, revenue +8%, FY27 guide raised
Revenue
Revenue increased 8% YoY to $105.4B in Q1, led by North American Pharma (+5% to $86.8B) and Oncology & Multispecialty (+33% to $14.2B). RxTS grew 9% to $1.6B and Medical-Surgical grew 4% to $2.8B. GLP-1 distribution revenue was $15B, up 24% YoY.
Profitability
Adjusted EPS rose 20% to $9.93. GAAP net income attributable to McKesson was $614M, down 22% due to a $293M non-cash redeemable non-controlling interest remeasurement, partially offset by strong operating growth.
Margins
Consolidated adjusted operating profit increased 16% to about $1.7B. Gross profit rose 13% to $3.7B, and operating expenses as a percentage of gross profit improved by roughly 150 basis points YoY, highlighting strong operating leverage.
Balance Sheet
McKesson ended Q1 with $5.2B cash and total liquidity of approximately $10B. Free cash flow was negative $372M, including $152M capex, but trailing 12-month free cash flow was about $6.1B; the company also completed a $2.25B Term Loan B and $1B revolver remained undrawn.
Key Risks
Medical-Surgical op profit fell 20% on mix and one-time costs; Q2 will face tough comps including a $51M prior-year gain in Oncology and $25M of Norway profit. Management flagged timing benefits in Q1 from product launches and generics, and policy uncertainty around 340B, IRA Part B, and WAC pricing remains.
Outlook
Full-year adjusted EPS guidance was raised to $44.20-$45.00, implying 13%-15% growth. Revenue growth is expected at 5%-9%, operating profit growth at 9%-13%, and free cash flow of $4.5-$4.9B.
Generated by AI · Q1 2027 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q1 2027 Q1 2027 2026-08-05
Q1 2027 saw 8% revenue growth to $105.4B and 20% adjusted EPS growth, with all major segments delivering double-digit operating profit increases. Full-year EPS guidance was raised, supported by strong fundamentals, robust specialty and technology-driven growth, and continued capital returns.
Q4 2026 Q4 2026 2026-05-07
Fiscal 2026 saw strong growth with revenues up 12% and adjusted EPS up 18%, driven by specialty and oncology platforms. FY27 guidance projects 12–14% EPS growth, continued capital returns, and progress on the Medical-Surgical Solutions separation.
Q3 2026 Q3 2026 2026-02-04
Delivered record revenue and double-digit adjusted EPS growth, driven by Oncology, Biopharma Services, and North American distribution. Raised full-year EPS guidance, completed European exit, and advanced Medical-Surgical separation, with strong cash flow and continued investment in technology.
Q2 2026 Q2 2026 2025-11-05
Second quarter fiscal 2026 saw 10% revenue growth to $103B and 39% EPS growth, driven by strong performance in North American Pharmaceutical, Oncology and Multispecialty, and Prescription Technology Solutions. Full-year EPS guidance was raised, with robust cash flow and continued portfolio transformation.
Q1 2026 Q1 2026 2025-08-06
Q1 revenue rose 23% to $97.8B and adjusted operating profit grew 9%, driven by strong specialty, oncology, and biopharma services. Fiscal 2026 EPS guidance was raised, with continued investment in automation, acquisitions, and shareholder returns supporting long-term growth.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.